Abstract: The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): wherein R1-R3 are as defined herein, or pharmaceutically acceptable salts or esters thereof; and a pharmaceutically acceptable carrier.

Abstract: A signal receiving circuit amplifies a radio frequency signal by using a first radio frequency amplifier, outputs a first amplified signal in a same phase, amplifies the radio frequency signal by using a second radio frequency amplifier, and outputs a second amplified signal at an inverse phase. A first mixer mixes a first local oscillator signal with the first amplified signal to obtain a first frequency mixing signal, and a second mixer mixes a second local oscillator signal with the second amplified signal to obtain a second frequency mixing signal, where a phase of the first local oscillator signal is opposite to a phase of the second local oscillator signal. After adding the first frequency mixing signal and the second frequency mixing signal, an output interface outputs the first frequency mixing signal and the second frequency mixing signal.

Abstract: A transceiver system is configured to concurrently send TX signals and receive RX signals on an antenna system in the same frequency band. A bi-directional frequency converter circuit modulates the TX signals and RX signals by a modulation frequency. The modulated TX signals and RX are frequency shifted so that they have different frequencies that are not in the same frequency band. For example, the TX signal may be shifted to a higher frequency and the RX signal may be shifted to a lower frequency. Filters can then be used to isolate the TX signal and the RX signal for transmission and/or processing.

Abstract: The present invention provides engineered branched chain ketoacid decarboxylase (KdcA) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered branched chain ketoacid decarboxylase (KdcA) polypeptides. In some embodiments, the engineered KdcA polypeptides are optimized to provide enhanced catalytic activity, as well as reduced sensitivity to proteolysis and increased tolerance to storage at elevated temperatures. The present invention also provides methods for the use of the compositions comprising the engineered KdcA polypeptides for therapeutic and industrial purposes.

Abstract: The present invention provides engineered phosphopentomutase (PPM) enzymes, polypeptides having PPM activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PPM enzymes are also provided. The present invention further provides compositions comprising the PPM enzymes and methods of using the engineered PPM enzymes. The present invention finds particular use in the production of pharmaceutical compounds.

Abstract: The present invention provides engineered phosphopentomutase (PPM) enzymes, polypeptides having PPM activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PPM enzymes are also provided. The present invention further provides compositions comprising the PPM enzymes and methods of using the engineered PPM enzymes. The present invention finds particular use in the production of pharmaceutical compounds.

Abstract: The present invention provides engineered penicillin G acylase (PGA) enzymes, polynucleotides encoding the enzymes, compositions comprising the enzymes, and methods of using the engineered PGA enzymes.

Abstract: The present invention provides engineered penicillin G acylase (PGA) enzymes, polynucleotides encoding the enzymes, compositions comprising the enzymes, and methods of using the engineered PGA enzymes.

Abstract: The present invention provides engineered RNA polymerase variants and compositions comprising these variants. The present invention further provides engineered T7 RNA polymerase variants and compositions comprising these variants. These variants have been evolved for selective incorporation of the m7G(5?)ppp(5?)m7G cap analog over GTP at the initiation of in vitro transcription. The present invention also provides methods for selective capping of RNA transcripts.

Abstract: The present invention provides engineered RNA polymerase variants and compositions comprising these variants. The present invention further provides engineered T7 RNA polymerase variants and compositions comprising these variants. These variants have been evolved for selective incorporation of the m7G(5?)ppp(5?)m7G cap analog over GTP at the initiation of in vitro transcription. The present invention also provides methods for selective capping of RNA transcripts.

Abstract: The present invention provides engineered penicillin G acylase (PGA) enzymes, polynucleotides encoding the enzymes, compositions comprising the enzymes, and methods of using the engineered PGA enzymes.

Abstract: A signal receiving circuit amplifies a radio frequency signal by using a first radio frequency amplifier, and outputs a first amplified signal in a same phase; amplifies the radio frequency signal by using a second radio frequency amplifier, and outputs a second amplified signal at an inverse phase. A first mixer mixes a first local oscillator signal with the first amplified signal to obtain a first frequency mixing signal; a second mixer mix a second local oscillator signal with the second amplified signal to obtain a second frequency mixing signal, where a phase of the first local oscillator signal is opposite to a phase of the second local oscillator signal; and after adding the first frequency mixing signal and the second frequency mixing signal, an output interface outputs the first frequency mixing signal and the second frequency mixing signal.

Abstract: The present invention provides engineered T7 RNA polymerase variants and compositions thereof. These variants have been evolved for selective incorporation of the symmetrical capped GTP analog over GTP at the initiation of in vitro transcription. The present invention also provides methods for using the variants provided herein. The present invention further provides for the use of the compositions provided herein.

Abstract: The present invention provides engineered penicillin G acylase (PGA) enzymes, polynucleotides encoding the enzymes, compositions comprising the enzymes, and methods of using the engineered PGA enzymes.

Abstract: The present invention provides engineered RNA polymerase variants and compositions comprising these variants. The present invention further provides engineered T7 RNA polymerase variants and compositions comprising these variants. These variants have been evolved for selective incorporation of the m7G(5?)ppp(5?)m7G cap analog over GTP at the initiation of in vitro transcription. The present invention also provides methods for selective capping of RNA transcripts.

Abstract: The present invention provides engineered phosphopentomutase (PPM) enzymes, polypeptides having PPM activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PPM enzymes are also provided. The present invention further provides compositions comprising the PPM enzymes and methods of using the engineered PPM enzymes. The present invention finds particular use in the production of pharmaceutical compounds.

Abstract: A time-to-digital converter is provided. The time-to-digital converter comprises an oscillator controller, an invertible oscillator and a measurement circuit. The oscillator controller receives a start signal and a stop signal and outputs a mode signal. The invertible oscillator is electrically connected with the oscillator controller for receiving the mode signal. The oscillation direction of the invertible oscillator is inverted according to the mode signal, and the invertible oscillator outputs plural delay signals. The measurement circuit is electrically connected with the invertible oscillator for receiving the plural delay signals. The measurement circuit receives a sampling signal, samples the plural delay signals in accordance with the sampling signal, and outputs an output signal.

Abstract: The communication receiver comprises a mixer being configured to mix the communication signal with a periodic mixing signal having a mixing frequency fC to obtain a mixed communication signal, wherein the mixed communication signal comprises a first frequency spectrum portion comprising the spectral region of interest being situated around a frequency fRF+fC and a second frequency spectrum portion comprising the spectral range of interest being situated around fRF?fC; a first demodulator being configured to demodulate a first frequency channel of the plurality of frequency channels within the spectral range of interest of the first frequency spectrum portion on the basis of a first local oscillator frequency fLO1; and a second demodulator being configured to demodulate a second frequency channel of the plurality of frequency channels within the spectral region of interest of the second frequency spectrum portion on the basis of a second local oscillator frequency fLO2.

Abstract: Integrated circuits, wafer level integrated III-V power device and CMOS driver device packages, and methods for fabricating products with integrated III-V power devices and silicon-based driver devices are provided. In an embodiment, a boost converter circuit includes an inductor; a power switch having a conducting state and blocking state; and a control circuit for controlling the power switch from the conducting state to the blocking state for controlling flow of the current in the inductor, wherein the control circuit comprises a silicon integrated circuit comprising bipolar CMOS transistors, wherein when the power switch comprises a first GaN transistor, and wherein the power switch and silicon integrated circuit are electrically and mechanically coupled by way of flip chip bonding.

Abstract: The present invention provides engineered T7 RNA polymerase variants and compositions thereof. These variants have been evolved for selective incorporation of the symmetrical capped GTP analog over GTP at the initiation of in vitro transcription. The present invention also provides methods for using the variants provided herein. The present invention further provides for the use of the compositions provided herein.